Key TakeawaysMorgan Stanley cut Novo Nordisk’s rating from Equal-weight to Underweight while maintaining a 250 Danish crown price targetShares declined approximately 2.4% during early Copenhagen market hoursSemaglutide represents 75% of the company’s revenue and confronts significant patent expiration challenges in the early-to-mid 2030sAnalysts project 2-3% revenue and EBIT expansion in 2027, trailing broader European pharmaceutical sector expectationsLimited positive catalysts identified before the company’s September 21 capital markets presentationMorgan Stanley delivered a bearish assessment of Novo Nordisk with an Underweight downgrade, triggering an immediate market reaction. Shares fell roughly 2.4% in Copenhagen trading after the announcement.Novo Nordisk A/S, NVOThe analyst team headed by Thibault Boutherin argued that the pharmaceutical giant’s present market valuation fails to account for a lackluster medium-term expansion trajectory. Their price objective remains unchanged at 250 Danish crowns, suggesting potential downside exceeding 10% from recent closing levels.Central to the bearish thesis is semaglutide, the compound powering blockbuster medications Ozempic and Wegovy. This single molecule generated 75% of the company’s entire revenue stream in 2026.This heavy concentration poses significant challenges during the early-to-mid 2030s timeframe, when semaglutide’s patent protection expires across Europe and the United States. Morgan Stanley’s financial models indicate the drug will still represent 59% of total sales in 2031, precisely when exclusivity loss begins impacting revenues.Underwhelming Expansion TrajectoryMorgan Stanley anticipates 2-3% revenue and EBIT expansion for 2027, aligning closely with market consensus estimates. However, between 2027 and 2030, analysts forecast just a 4% compound annual growth rate for both top-line and EBIT metrics.These projections lag considerably behind the 4% revenue and 7% EBIT growth rates Morgan Stanley expects from the wider European pharmaceutical industry during the identical timeframe.While the bank acknowledges Novo’s oral obesity product pipeline could achieve $10 billion in annual sales by 2031, analysts cautioned this milestone “will not be enough to offset pricing and competitive headwinds.”A proprietary Morgan Stanley physician survey encompassing 200 primary care practitioners revealed increasing GLP-1 medication adoption overall. Yet the research simultaneously highlighted anticipated market share erosion for Novo during the coming 18 months, driven by Eli Lilly’s existing portfolio and its forthcoming retatrutide candidate, projected to launch in 2027.Trading Multiple and Upcoming Investor EventFrom a valuation perspective, Novo currently trades at 12.5 times projected 2027 earnings. This represents a 7% discount relative to European large-cap pharmaceutical comparables, yet commands a 35% premium versus global competitors confronting comparable patent expiration challenges, including Sanofi and GSK.Morgan Stanley specifically highlighted this valuation disparity, emphasizing the premium appears “more pronounced” compared to GSK at 10x and Sanofi at 8x multiples.The company’s capital markets day is slated for September 21. Morgan Stanley anticipates management will reinforce its oral obesity therapeutic strategy and deliver progress reports on business development initiatives spanning MASH and chronic kidney disease indications.The research team indicated they perceive “limited scope for major announcements” during this investor presentation.One scenario that could support share price appreciation would involve oral obesity medications capturing greater patient market penetration than current forecasts anticipate and demonstrating superior resilience against competitive pressures and generic entry compared to existing models.Morgan Stanley’s Underweight rating classification signals analyst expectations that the stock will underperform relative to sector peers moving forward.The post Novo Nordisk (NVO) Stock Drops After Morgan Stanley Downgrade on Patent Cliff Concerns appeared first on Blockonomi.